A Study of QLF32101 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Status:
Not yet recruiting
Trial end date:
2024-12-21
Target enrollment:
Participant gender:
Summary
This study aimed to evaluate the safety,tolerability and preliminary efficacy of QLF32101
administered intravenously and subcutaneously in patients with R/R, AML.